One-capsule, once-daily dosing for adults with TD or HD chorea
See dosing for TARDIVE DYSKINESIA (TD)
See dosing for Huntington’s disease (hd) chorea
Only INGREZZA offers a
therapeutic dose from Day 11:
No other VMAT2 inhibitor can offer
the simplicity of INGREZZA1:
Why wait?
Therapeutic dose from Day 1
Why titrate?
No complex titration
Why overcomplicate?
Start with INGREZZA
INGREZZA IS THE ONLY VMAT2 INHIBITOR TO OFFER A SPRINKLE FORMULATION1
Actor portrayal
GET YOUR PATIENTS STARTED ON INGREZZA RIGHT AWAY
Request samples of INGREZZA® (valbenazine) capsules today to start patients on treatment
The only VMAT2 inhibitor that offers an effective starting dosage you can adjust based on response and tolerability1
DOSING FOR Tardive dyskinesia (TD)
DOSING FOR
Tardive dyskinesia
DOSING FOR Huntington’s disease (HD) chorea
DOSING FOR
HD chorea
Three effective doses and the ability to get to the recommended dose after 1 week1
Start on INGREZZA 40 mg
Not actual size
Start on INGREZZA 40 mg
Continue on INGREZZA
40 mg, 60 mg, or 80 mg
Continue on INGREZZA
40 mg, 60 mg, or 80 mg
- Initial dosage of INGREZZA is 40 mg once daily for one week1
- After the first week, 80 mg is recommended once daily, but 40 mg or 60 mg once daily may be considered based on individual treatment needs, response, and tolerability1
Treat TD while preserving your patient’s antipsychotic regimen
Patients in the clinical trials were allowed to remain on their stable psychiatric treatment regimen1:
85%
took second-generation
antipsychotics
27%
took first-generation
antipsychotics
In KINECT 3, the most common types of concomitant medications were2,3:
- Antipsychotics (85.5%)
- Antidepressants (66.5%)
- Anticholinergics (37.0%)
- Antiepileptics (35.2%)
- Anxiolytics (27.7%)
- ACE inhibitors (25.1%)
Not actual size
Start on
INGREZZA 40 mg
once daily for two weeks
Followed by
INGREZZA 60 mg
once daily for two weeks
INGREZZA 80 mg
once daily
Not actual size
Start on INGREZZA 40 mg
once daily for two weeks
Followed by INGREZZA 60 mg
once daily for two weeks
INGREZZA 80 mg
once daily
The initial dosage for INGREZZA is 40 mg once daily. Increase the dose in 20 mg increments every two weeks to the recommended dosage of 80 mg once daily. A dosage of 40 mg or 60 mg once daily may be considered depending on response and tolerability.1
Even your patients with some complex considerations may benefit from INGREZZA1
DRUG INTERACTIONS AND DOSING RECOMMENDATIONS1
For patients with complex medical histories:
Moderate to severe hepatic impairment
Recommended dosage 40 mg once daily
Known CYP2D6 poor metabolizers
Recommended dosage 40 mg once daily
For patients taking the following medications:
Strong CYP3A4 inducers
(eg, rifampin, carbamazepine, phenytoin, St. John’s wort)
Concomitant use not recommended
Strong CYP3A4 inhibitors
(eg, itraconazole, ketoconazole, clarithromycin)
Recommended dosage 40 mg once daily
Strong CYP2D6 inhibitors
(eg, paroxetine, fluoxetine, quinidine)
Recommended dosage 40 mg once daily
MAOIs
(eg, isocarboxazid, phenelzine, selegiline)
Avoid concomitant use, or within 14 days of discontinuing therapy with an MAOI
Digoxin
Digoxin concentrations should be monitored when coadministered; may need to adjust digoxin dose
MAOIs, monoamine oxidase inhibitors.
DOSING RECOMMENDATIONS FOR SPECIAL POPULATIONS1
For elderly patients
No dose adjustment required
In 3 randomized, placebo-controlled studies of INGREZZA in patients with tardive dyskinesia, 16% were 65 years and older. The safety and effectiveness were similar in patients older than 65 years compared to younger patients.1
In the randomized, placebo-controlled study of INGREZZA in patients with chorea associated with Huntington's disease, 15% were 65 years and older. This study did not include sufficient numbers of subjects aged 65 and older to determine whether they responded differently from younger subjects.1
For patients with renal impairment
No dose adjustment required
Dosage adjustment is not necessary for patients with mild, moderate, or severe renal impairment. INGREZZA does not undergo primary renal clearance.1
For patients with hepatic impairment
Dosage reduction of INGREZZA is recommended for patients with moderate or severe hepatic impairment. Patients with moderate to severe hepatic impairment (Child-Pugh score 7 to 15) had higher exposure of valbenazine and its active metabolite than patients with normal hepatic function. The recommended dosage for patients with moderate or severe hepatic impairment is INGREZZA 40 mg once daily.1
For patients with increased cardiac risk
INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.1
UNIQUELY SELECTIVE
Only INGREZZA exclusively delivers one primary metabolite (+ α) for potent and selective inhibition of VMAT21,4,5
EXPLORE PHARMACOLOGYEXPLORE FINANCIAL ASSISTANCE OPTIONS
$10 or less out-of-pocket is what most patients pay for INGREZZA6
SAVINGS & SUPPORTREFERENCES:
- INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.
- Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484.
- Data on file. Neurocrine Biosciences, Inc.
- Harriott ND, Williams JP, Smith EB, Bozigian HP, Grigoriadis DE. VMAT2 inhibitors and the path to INGREZZA (valbenazine). Prog Med Chem. 2018;57(1):87-111.
- Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361(3):454-461.
- Measured by NDC; data on file as of Q3 2023. Neurocrine Biosciences, Inc.